Clinical Validation of a Non-Invasive Electrodermal Biofeedback Device Useful for Reducing Chronic Perceived Pain and Systemic Inflammation

Hormones (Athens). 2019 Jun;18(2):207-213. doi: 10.1007/s42000-019-00098-5. Epub 2019 Feb 25.

Abstract

Background: This study was performed to evaluate the potential clinical usefulness of a new non-invasive electrodermal biofeedback device in reducing perceived pain levels and chronic systemic inflammation.

Materials and methods: This multicenter study was designed and coordinated by BioTekna, included 20 general practice medical centers, took place between June 2010 and January 2011, and was validated clinically at the National and Kapodistrian University of Athens, Greece. The study participants were 1015 Caucasian men (401) and women (614), while the placebo-treated controls were 950 Caucasian men (500) and women (450). Patients were aged between 30 and 86 years (average age about 50 years) and all suffered from chronic pain and other medically unexplained symptoms (MUS). The RegMatEx electrodermal biofeedback device (brand BioTekna - Biomedical Technologies, Marcon, Venice, Italy) was used to evaluate the clinical efficacy of electrodermal biofeedback in reducing the level of pain perceived by decreasing the chronic systemic inflammation of the subjects. All subjects received 6 × 30 min sessions of electrodermal or placebo biofeedback given twice a week over 3 weeks. Perceived pain was evaluated using the Numeric Rating Scale (NRS) for pain, while systemic inflammation was examined with measurements of morning circulating C-reactive protein (CRP) concentrations.

Results: Perceived pain in the treatment group was significantly lessened in the NRS scale (p < 005), while circulating CRP concentrations were also decreased (p < 0.05). Parallel placebo studies showed no changes in perceived pain or morning serum CRP concentrations.

Discussion: Use of the electrodermal biofeedback RegMatEx device was associated with reduced pain perception and decreased chronic systemic inflammation, with stability over time. This did not occur in the placebo-treated group. The symptomatology of the treated patients significantly improved in terms of pain relief as shown on the NRS scale, and this was accompanied by reported improvements in mobility, mood, and quality of life.

Conclusions: The RegMatEx electrodermal biofeedback procedure is a non-invasive and easy to use therapeutic method, free of side effects, with high patient acceptability, excellent efficacy, and duration of effect, and, hence, a valuable tool in the treatment of chronic pain and inflammation.

Keywords: C-reactive protein; Chronic inflammation; Electrodermal biofeedback; Pain; RegMatEx; Stress.

Publication types

  • Controlled Clinical Trial
  • Multicenter Study
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biofeedback, Psychology / physiology*
  • Chronic Pain / physiopathology
  • Chronic Pain / therapy*
  • Equipment and Supplies*
  • Female
  • Galvanic Skin Response / physiology*
  • Greece
  • Humans
  • Inflammation / complications
  • Inflammation / therapy*
  • Male
  • Middle Aged
  • Pain Management* / instrumentation
  • Pain Management* / methods
  • Pain Perception / physiology
  • Treatment Outcome